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Summary
NADH pyrophosphatase (NudC) catalyses the
hydrolysis of NAD(H) to AMP and NMN(H) [nicotina-
mide mononucleotide (reduced form)]. NudC multiple
sequence alignment reveals that homologues from
most Mycobacterium tuberculosis isolates, but not
other mycobacterial species, have a polymorphism at
the highly conserved residue 237. To elucidate the
functional signiﬁcance of this polymorphism, com-
parative analyses were performed using representa-
tive NudC isoforms from M. tuberculosis H37Rv
(NudCRv) and M. bovis BCG (NudCBCG). Biochemical
analysis showed that the P237Q polymorphism pre-
vents dimer formation, and results in a loss of enzy-
matic activity. Importantly, NudCBCG was found to
degrade the active forms of isoniazid (INH), INH-NAD
and ethionamide (ETH), ETH-NAD. Consequently,
overexpression of NudCBCG in Mycobacterium
smegmatis mc2155 and M. bovis BCG resulted in a
high level of resistance to both INH and ETH. Further
genetic studies showed that deletion of the nudC
gene in M. smegmatis mc2155 and M. bovis BCG
resulted in increased susceptibility to INH and ETH.
Moreover, inactivation of NudC in both strains caused
a defect in drug tolerance phenotype for both drugs in
exposure assays. Taken together, these data suggest
that mycobacterial NudC plays an important role in
the inactivation of INH and ETH.
Introduction
World Health Organization estimates suggest that Myco-
bacterium tuberculosis kills over 1 million people each
year and causes over 8 million incident cases of tubercu-
losis (TB). The ever increasing incidence of drug-resistant
TB further compounds this global health crisis. By the
year 2007, there were approximately 0.5 million reported
cases of multidrug-resistant TB. Moreover, by November
2009, 57 countries and territories had reported at least
one case of extensively drug-resistant TB (World Health
Organization, 2009). To counter this increasing threat of
drug resistance, it is critical to understand fundamental
aspects of TB-related biology. Such studies will not only
uncover cellular mediators of susceptibility and resistance
to existing anti-TB drugs, but will also provide new drug
targets for the design of novel therapeutic agents.
Isoniazid (INH) was ﬁrst described in the early 1900s,
and since 1952 has prevailed as one of the most potent
and widely administered anti-TB drugs (Bernstein et al.,
1952; Fox, 1952). Over the last few decades, several
genetic and biochemical studies have delineated the
series of events involved in INH action. Upon entry into
the cell, the hydrazide group of INH is activated by
catalase-peroxidase (KatG) to generate an isonicotinic
acyl radical. Once formed, this radical spontaneously
reacts with NAD(H) at the 4th position of the nicotinamide
ring, yielding an INH-NAD adduct (Zhang et al., 1992;
Johnsson and Schultz, 1994; Rozwarski et al., 1998;
Wilming and Johnsson, 1999). This adduct acts as a
slow-onset, tight-binding inhibitor of the NADH-dependent
enoyl-ACP reductase (InhA) of the mycobacterial fatty
acid synthase II (Banerjee et al., 1994; Rozwarski et al.,
1998; Wilming and Johnsson, 1999; Rawat et al., 2003).
Competitive inhibition of NADH binding by INH-NAD
results in cessation of mycolic acid biosynthesis and cel-
lular lysis (Takayama et al., 1972; Vilchèze et al., 2000).
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nized within the ﬁrst year of the clinical use of INH as an
anti-tubercular drug (Middlebrook and Cohn, 1953).
Several mechanisms of INH resistance have since been
described. These include failure to form the INH-NAD
adduct due to loss of function mutations in katG (Heym
and Cole, 1992; Zhang et al., 1992; Heym et al., 1995);
failure of the INH-NAD adduct to associate with the target
due to active-site mutations in inhA (Banerjee et al., 1994;
Vilchèze et al., 2006); out-competition of the INH-NAD
adduct with excessive cytoplasmic levels of NADH due to
mutations in ndh (Miesel et al., 1998; Lee et al., 2001;
Vilchèze et al., 2005); and titration of the INH-NAD adduct
by increased expression of InhA due to promoter-up
mutations (Larsen et al., 2002; Vilchèze et al., 2006).
Importantly, resistance mechanisms for up to 22% of the
INH-resistant M. tuberculosis clinical isolates still remain
unknown (Hazbon et al., 2006).
The action of INH has been shown to be linked with NAD
metabolism in M. tuberculosis, early studies showed that
the NAD content of M. tuberculosis decreased when cells
were exposed to INH (Bekierkunst, 1966). However, the
NAD metabolism of M. tuberculosis has not been thor-
oughly investigated in spite of efforts made during the last
few years (Boshoff et al., 2008; Vilchèze et al., 2010), and
the link between INH and NAD metabolism is still unclear.
Ethionamide (ETH) is an important component of
second-linetherapyforthetreatmentofmultidrug-resistant
TB, and shares a common target with INH. Like INH, ETH
is a pro-drug that requires activation to form adducts with
NAD that subsequently inhibit InhA(Banerjee et al., 1994;
Baulard et al., 2000; DeBarber et al., 2000; Vannelli et al.,
2002; Wang et al., 2007). Resistance to ETH has been
reported to result from various mechanisms, including
mutationsalteringEthA/EthR(Baulardet al.,2000;DeBar-
ber et al., 2000; Morlock et al., 2003), InhA and its pro-
moter (Banerjee et al., 1994; Larsen et al., 2002; Vilchèze
et al., 2006), the NADH dehydrogenase encoded by ndh
(Miesel et al., 1998; Vilchèze et al., 2005), and the MshA
enzyme which is involved in mycothiol biosynthesis
(Vilchèze et al., 2008). However, the mechanism of resis-
tance to ETH of 19% of the ETH-resistant isolates remains
unknown (Brossier et al., 2011).
Rv3199c of M. tuberculosis H37Rv and BCG_3224c of
Mycobacterium bovis BCG Pasteur strain 1173P2 (hereaf-
ter referred to as M. bovis BCG) encode a NADH pyro-
phosphatase (NudC, EC 3.6.1.22), which belongs to the
Nudix hydrolase superfamily of nucleotide pyrophos-
phatases.The Nudix hydrolases comprise a large family of
proteins characterized by a highly conserved 23-amino-
acid Nudix motif (Nudix box), GX5EX7REUXEEXGU,
where U represents a bulky, hydrophobic, amino acid,
usually Ile, Leu or Val (Bessman et al., 1996). The
sequenceSQPWPFPQSlocated10residuesdownstream
of the Nudix box is found in many characterized NADH
hydrolases and may confer pyridine nucleotide speciﬁcity
(Dunn et al., 1999). The Nudix superfamily proteins
(InterPro IPR000086; PfamPF00293) act on substrates
with a general structure (nucleoside diphosphate linked
to another moiety X, NDP-X), yielding NMP and P-X
(Bessman et al., 1996). The hydrolysis of dinucleotide
pyrophosphatesrequiresdivalentmetalions(Mg2+orMn2+)
and yields two mononucleoside 5′-phosphates (Frick and
Bessman, 1995). In addition to NADH and NAD+, structur-
ally related compounds like NADPH, ADP-ribose and dia-
denosine polyphosphates are also substrates of this
superfamily of proteins (Frick and Bessman, 1995).
Since NudC has a rather broad range of substrates as
mentioned above, we speculated that mycobacterial
NudC can hydrolyse the INH-NAD and ETH-NAD
adducts, resulting in the inactivation of these inhibitors.
Thus, overexpression of NudC should lead to INH or ETH
resistance in mycobacteria. On the contrary, inactivation
of NudC should increase susceptibility to INH and ETH.
To verify this hypothesis, we ﬁrst characterized NudC
from M. tuberculosis H37Rv (NudCRv) and M. bovis BCG
(NudCBCG) biochemically. Their abilities to hydrolyse INH-
NAD or ETH-NAD were veriﬁed by mass-spectrometry
and also enzymatic assays. The corresponding NudC-
encoding genes were then overexpressed in Mycobacte-
rium smegmatis mc2155 and M. bovis BCG to examine
changes in drug susceptibility. Furthermore, nudC of
M. smegmatis mc2155 and M. bovis BCG was deleted to
look into the changes of drug susceptibilities.
Results
Alignment of NudC protein sequences from
different origins
MycobacteriumtuberculosisH37RvnudCgene(Rv3199c)
encoding NudC consists of 942 base pairs corresponding
to 313 amino acid residues. Multiple alignments of myco-
bacterial NudC show that M. tuberculosis NudC has a
polymorphism (P237Q) not present in any other myco-
bacteria which lies in a very conserved region of NudC
(SQPWPFPQS) and is predicted to confer pyridine nucle-
otide speciﬁcity (Dunn et al., 1999) (Fig. 1A). Subse-
quently, alignments of NudC between M. bovis BCG and
M. tuberculosis clinical isolates (http://www.broadinstitute.
org/annotation/genome/mycobacterium_tuberculosis_
diversity/GenomesIndex.html) were also performed and
multiple differences were noted (Fig. 1B). There were two
amino acid differences (residues 254 and 268) between
NudC from M. bovis BCG and M. tuberculosis K85
(Mostowy et al., 2004), and between M. tuberculosis T85
and M. tuberculosis w_148 (Hirsh et al., 2004; Gagneux
et al., 2006) (residues 237 and 239). However, the
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clinical isolates M. tuberculosis T46, M. tuberculosis
CPHL_A and M. tuberculosis EAS054 (Hirsh et al., 2004;
Mostowyet al.,2004)wasfoundtobeidenticaltoNudCBCG.
nudC genes from a further 137 M. tuberculosis clinical
isolates from China were sequenced and analysed
(Table S1). Results showed that the P237Q mutation of
NudCwaspresentinalloftheseisolates.Inaddition,about
75% of these isolates harboured a second mutation
(P239R) in the NudC conserved signature sequence, and
a few isolates were found to harbour mutations at other
sites.
Physicochemical characterization of NudCRv
and NudCBCG
NudCRv and NudCBCG were successfully expressed in
Escherichia coli BL21 (DE3) by using the expression
Fig. 1. Multiple alignments of NudC from different origins. Sequences aligned using CLUSTAL W.
A. Alignments of NudC from E. coli W3110 (AP_003822), M. tuberculosis H37Rv (NP_217715), M. smegmatis mc
2155 (YP_886312) and
M. bovis BCG (YP_979308). Conserved residues (Nudix box and NudC characteristic sequences) in NudC are highlighted ().
B. Alignments of NudC from different M. tuberculosis clinical isolates and M. bovis BCG. Only regions containing differences are highlighted
(grey and ).
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tag, which has been shown to be very effective in reduc-
ing inclusion body formation (LaVallie et al., 1993). SDS-
PAGE analysis shows (Fig. 2A) that the molecular weight
of puriﬁed recombinant NudC (fused with Trx tag) is about
51 kDa, which is consistent with its theoretical molecular
weight.
The native molecular weight of recombinant NudC was
determined by gel exclusion chromatography.As shown in
Fig. 2C, NudCRv has two adjacent elution peaks (peak 1
Fig. 2. Analysis of NudC native structure.
A. Nickel affinity-puriﬁed NudCBCG (lane 1, arrow) and NudCRv (lane 2, arrow) were electrophoresed on 10% (v/v) SDS-PAGE; lane 3: protein
molecular weight marker.
B. Native PAGE of puriﬁed NudCBCG (lane 1) and NudCRv (lane 2) on 9% (v/v) PAGE. Two NudC bands were detected and are indicated as a2
and a (arrows indicated).
C. Gel exclusion chromatography analysis of the native structure of puriﬁed NudCRv and NudCBCG. Nickel affinity-puriﬁed NudCBCG and NudCRv
were concentrated then loaded onto a Superdex 200 10/300GL column and eluted.
D and E. Analytical ultracentrifugation analysis of the native structure of puriﬁed NudCBCG (D) and NudCRv (E). Expected products are indicated
by arrows.
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one peak (peak 1). Subsequent SDS-PAGE analysis
revealed that both peaks 1 and 2 contained recombinant
NudC proteins, NudCBCG being present mainly in elution
peak 1 while NudCRv was present mainly in peak 2
(Fig. 2C).According to results from elution curve analysis,
it was clear that NudCBCG was eluted faster than NudCRv,
suggesting that NudCBCG and NudCRv may have two struc-
tural forms under native conditions. The native molecular
weight of recombinant NudC was further analysed by
analytical ultracentrifugation; recombinant NudCBCG was
estimated to be about 80 kDa, although a small portion of
protein was estimated to be about 40 kDa (Fig. 2D). The
molecular weight of NudCRv was estimated to be about
50 kDa, although a small portion of protein was estimated
to be about 100 kDa (Fig. 2E). The molecular weights of
recombinant NudC estimated from gel exclusion chroma-
tography analysis were thus consistent with results from
analytical ultracentrifugation. To further analyse differ-
ences in protein native structure between NudCRv and
NudCBCG, non-denaturing PAGE experiments were per-
formed (Fig. 2B). Under non-denaturing conditions two
bands were observed for both proteins after staining.
NudCBCG was present mainly in the upper-band (possible
dimeric form, indicated as a2), but NudCRv was present
mainly in the lower band (possible monomeric form, indi-
cated as a). These data, combined with data from gel
exclusion chromatography and analytical ultracentrifuga-
tion, suggest that NudCRv is mainly present as a mono-
meric protein, while NudCBCG is mainly dimeric under
native conditions.
NudC in most M. tuberculosis clinical isolates from
China harboured double mutations (P237Q and P239R)
(hereafter referred to as NudCQR) which were identical to
those of M. tuberculosis clinical isolates T85 and W_148.
This NudC double mutant protein was puriﬁed and then
analysed by gel exclusion chromatography (Fig. S1A) and
native PAGE (Fig. S1B) as described above. Results
showed that NudCQR mainly forms a monomeric protein
and small of dimeric protein under native conditions.
Taken together, our results indicate that residue 237 of
NudCRv plays an important role in maintaining its dimeric
structure. As a consequence, the mutation of this residue
(P237Q) in M. tuberculosis NudC leads to the failure of
protein dimer formation. In addition, residue 239 of NudC
also affects dimer formation.
Enzymatic assays of NudCBCG and NudCRv
Results from the alignment of M. tuberculosis NudC with
NudC from other species show that the Nudix box and
NudC characteristic sequences are highly conserved.
NADH has already been shown to be the substrate
favoured over all other nucleoside diphosphate deriva-
tives by NudC from other species (Frick and Bessman,
1995; Bessman et al., 1996). In addition, divalent metal
ions have been shown to be essential for NudC enzymic
activity, with the most efficient stimulators being Mg2+ and
Mn2+, as previously reported (Frick and Bessman, 1995).
NADH/NAD+ hydrolysis by NudC in the presence of
different metal ions was veriﬁed according to a standard
protocol (Frick and Bessman, 1995). Parallel experiments
were performed for NudCRv and NudCBCG. As shown in
Table 1, NudCBCG and NudCRv differ in several respects.
First, in the presence of Mg2+, NudCRv barely hydrolysed
either NADH or NAD+, whereas hydrolysis by NudCBCG
was signiﬁcant, and showed a marked preference for
NADH over NAD+. Second, in the presence of Mn2+, NudC
from both species could hydrolyse NADH, but the speciﬁc
activity of NudCRv was only approximately one-ﬁfth that of
NudCBCG. Third, even in the presence of Mn2+, NudCRv
could barely hydrolyse NAD+. Other than Mg2+ and Mn2+,
NudCBCG showed some activity on NADH in the presence
of Fe2+ as well. However, neither enzyme had detectable
activity in the presence of Ca2+,C u 2+,Z n 2+ or Fe3+.
In addition to NADH and NAD+, several nucleotide pyro-
phosphate analogues (NADP+, NADPH, ADP-ribose)
were also tested as substrates for NudCRv and NudCBCG,
and their relative activities are shown in Table S2. As
expected, NADH was favoured over all other substrates
Table 1. Comparison of speciﬁc activities of NudCRv and NudCBCG in the presence of different metal ions.
a
M. bovis BCG (U·mg
-1) M. tuberculosis H37Rv (U·mg
-1)
NADH NAD
+ NADH NAD
+
Mg
2+ 1.59  0.2 0.03  0.01 0.02  0.01 0
Mn
2+ 1.44  0.1 0.58  0.08 0.29  0.1 0.05  0.03
Zn
2+ 0.06  0.01 0.01  0.01 0.05  0.01 0.04  0.01
Ca
2+ 000 0
Cu
2+ 000 0
Fe
3+ 0.02  0.01 0 0.03  0.01 0
Fe
2+ 0.39  0.05 0.05  0.02 0.03  0.01 0
a. Measurements were performed in triplicate. Values are means  standard deviations.
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substrates, consistent with results for NudC from other
sources (Xu et al., 2000). NudCBCG was found to have a
broader range of substrates than NudCRv.
The enzymatic activity of NudCQR from a representative
M. tuberculosis clinical isolate was also determined. The
enzymatic activity of this double mutant could hardly be
detected in the presence of any metal ion (Mg2+,M n 2+ or
any other ion), no matter what substrate was used.
Taken together, these results indicate that residue 237
of M. tuberculosis NudC is important, not only for its
dimerization, but also for its metal ion binding and enzy-
matic activity. Residue 239 may also play a role in its
enzymatic activity.
Using NADH as the substrate, the optimal pH and
temperature of NudCBCG were determined to be pH 8.0
and 40°C respectively (Fig. S2A and B). However,
enzyme activity rapidly decreased below pH 7.5, or when
the temperature was below 35°C or above 45°C.
NudCBCG hydrolyses the INH-NAD and
ETH-NAD adducts
As described above, NudC from both M. bovis BCG and
M. tuberculosis were veriﬁed to be NADH pyrophos-
phatases, and NudCBCG was shown to have a rather broad
range of substrates. Since INH-NAD and ETH-NAD
adducts are analogues of NAD, we wondered whether
NudCBCG might be also able to hydrolyse it. To test this
hypothesis, INH-NAD and ETH-NAD adducts were syn-
thesized and puriﬁed according to published protocols
(Lei et al., 2000; Nguyen et al., 2001; 2002; Wang et al.,
2007). Synthesized INH-NAD (Fig. S3) and ETH-NAD
(Fig. S4) adducts were analysed by HPLC-MS (Figs S3A
and S4A) and UV/VIS spectrometry (Figs S3B and S4B),
and results obtained were found to be consistent with
previous reports (Lei et al., 2000; Nguyen et al., 2001;
2002; Wang et al., 2007).
After incubation of INH-NAD or ETH-NAD with NudC,
the reaction mixture was ﬁltered through a Microcon 3
centricon ﬁlter unit to remove all proteins. Filtrates col-
lected were then analysed by HPLC-MS, and results indi-
cated that NudCBCG could hydrolyse the INH-NAD and
ETH-NAD adducts in the presence of Mg2+, yielding AMP
[(M-H)-] (peak of m/z 346) and INH-NMNH [(M-H)-] (peak
of m/z 440) (Fig. 3A) or AMP [(M-H)-] (peak of m/z 346)
and ETH-NMNH [(M-H)-] (peak of m/z 468) (Fig. 3D).
However, NudCRv could not hydrolyse the INH-NAD or
ETH-NAD adducts, and only had a peak of m/z 769
[(M-H)-] representing the intact INH-NAD adduct (Fig. 3B)
or a peak of m/z 797 [(M-H)-] representing the ETH-NAD
adduct (Fig. 3C).
Results indicated that the NudCQR could not hydrolyse
INH-NAD or ETH-NAD adduct, and only had a peak of
m/z 769 [(M-H)-] representing the intact INH-NAD adduct
(Fig. S5) or m/z 797 [(M-H)-] representing the ETH-NAD
adduct (Fig. S6).
Overexpression of NudC in mycobacteria
The nudC gene from M. bovis BCG and M. tuberculosis
H37Rv were both cloned into pMV261. The resulting
plasmids pMV261-NudCBCG, pMV261-NudCRv and empty
vector pMV261 were electroporated into M. smegmatis
mc2155, yielding mc2155 pMV261::nudCBCG,m c 2155
pMV261::nudCRv and mc2155 pMV261 respectively. To
conﬁrmtheoverexpressionofNudCRvandNudCBCGinvivo,
polyclonal anti-NudCRv and anti-NudCBCG antibodies were
raised. Western blotting showed that NudC from both
species was expressed successfully in M. smegmatis
mc2155 (Fig. S7).
As mentioned above, since NudCBCG is able to hydrolyse
the INH-NAD and ETH-NAD adducts and thus inactivate
them, overexpression of this gene should result in INH and
ETH resistance. Subsequently, tests for drug susceptibility
toINH,ETH,Rifampicin(RIF)andEthambutol(EMB)were
performed on the NudCBCG overexpressing M. smegmatis
mc2155 strain (mc2155 pMV261::nudCBCG). As shown in
Table 2,mc2155pMV261::nudCBCGwasco-resistanttoINH
and ETH, with 20- to 40-fold increases in MIC (Minimum
inhibitory concentration) for each compound, but its sus-
ceptibility to the other two drugs was not changed. The
susceptibility of mc2155 pMV261::nudCRv and mc2155
pMV261 to these four drugs was not changed. These
results suggest that the co-resistance of mc2155
pMV261::nudCBCG to INH and ETH was caused by overex-
pression of NudCBCG, and not from other causes. Similarly,
overexpression of M. smegmatis mc2155 NudC (NudCSm)
in M. smegmatis mc2155 (mc2155 pMV261::nudCSm) also
resulted in a high level of resistance to both INH and ETH
and susceptibility to the other two drugs (RIF and EMB)
was not changed (Table 2).
Recombinant plasmids pMV261-NudCBCG, pMV261-
NudCRv and empty vector pMV261 were electroporated
into M. bovis BCG yielding BCG pMV261::nudCBCG, BCG
pMV261::nudCRv and BCG pMV261 respectively. We
found that the efficiency of transformation of pMV261-
NudCBCG was extremely low in comparison with that of
pMV261-NudCRv and the blank vector pMV261 (less than
20 transformants per mg plasmid versus thousands of
transformants per mg plasmid). To verify the transformants
obtained, speciﬁc sequences from the overexpression
vector containing nudC were ampliﬁed and then
sequenced. Interestingly, most sequences ampliﬁed from
pMV261-NudCBCG transformants contained deletions and
mutationsofthenudCgene,buttherewerenomutationsin
thechromosomalcopyofnudCgene(datanotshown),and
only a very few transformants (about one in 30) had an
1380 X.-D. Wang etal. 
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of the overexpression of NudC may require secondary
mutations. A very similar phenomenon was also observed
inM. tuberculosisH37Ra,suggestingthatunlikeM. smeg-
matis mc2155, overexpression of functional NudC in slow-
growing mycobacteria is not tolerated. This may reﬂect
differences in NAD metabolism between fast and slow
growing mycobacteria.
Subsequent drug susceptibility tests showed that, BCG
pMV261::nudCBCG was also co-resistant to INH and ETH,
whereas the susceptibility of BCG pMV261::nudCRv and
BCG pMV261 to these two drugs was unchanged
(Table 2). Susceptibility to RIF and EMB in these strains
also remained unchanged (Table 2).
Inactivation of nudC resulted in increased susceptibility
to both INH and ETH
To further investigate the physiological role of mycobac-
terial nudC on cellular metabolism of INH and ETH, the
nudC gene was deleted from M. smegmatis mc2155,
M. bovis BCG and M. tuberculosis H37Ra and veriﬁed by
PCR (Fig. S8). As expected, the M. smegmatis mc2155,
M. tuberculosis H37Ra and M. bovis BCG strains in
which nudC was knocked out, mc2155 DnudC and BCG
DnudC, were more sensitive to both INH and ETH in MIC
testing; however, the susceptibility of the M. tuberculosis
H37Ra nudC knock out strain (H37Ra DnudC) to these
two drugs was unchanged (Table 2). Complemented
strains mc2155 DnudC pMV261::nudCSm and BCG DnudC
pMV261::nudCBCG also showed resistance to both INH
and ETH (Table 2), consistent with results obtained in our
nudC overexpression experiments. NudC was also over-
expressed in the complemented strains and the level of
NudC expressed was much higher than that in the
wild-type strain, also conferring resistance to INH and
ETH on these complemented strains. Susceptibilities
to RIF and EMB remained unchanged in these strains
(Table 2).
Drug exposure experiments were performed and results
showed that both mc2155 DnudC and BCG DnudC had a
defect in the INH tolerance phenotype (Fig. 4Aand B).The
INH killing curve of mc2155 DnudC differed from that of the
wild-type strain. Deletion of nudC resulted in greater killing
in the mc2155 DnudC mutant strain throughout the course
of treatment (96 h) than in the wild-type strain at the same
concentration of INH. In the wild-type strain, the killing
effect of INH peaked after 24 h of treatment, and then
bacteria started to grow again. In the mc2155 DnudC
mutant, the killing effect of INH was plateaued between 24
and 60 h, but increased thereafter as INH continued to
inhibit the growth of the bacteria (Fig. 4A).
Although deletion of M. bovis BCG nudC only resulted
in an about 1 log-fold increase in killing by INH compared
with the wild-type strain (Fig. 4B), it led to continuous
killing by ETH (Fig. 4C). In the wild-type strain, the killing
effect of ETH peaked after 7 days of treatment, and then
bacteria began to grow again. However, in the BCG
DnudC mutant, the killing effect continued to 21 days of
treatment.
These results provide further strong support showing
that, although previously unrecognized, mycobacterial
NudC plays a role in the cellular metabolism of INH and
ETH which is very important for the action and also the
tolerance of these two drugs.
Mycolic acid analysis of mycobacteria following INH or
ETH treatment
As mentioned above, overexpression of NudCBCG in
M. smegmatis mc2155 and M. bovis BCG resulted in
resistance to INH and ETH, while deletion of the nudC
Table 2. Drug susceptibility tests of mycobacterial strains.
Strain Description
MIC (mgm l
-1)
INH ETH EMB RIF
mc
2155 M. smegmatis mc
2155 5 10 0.5 10
mc
2155 pMV261 mc
2155 transformed with pMV261 5 10 0.5 10
mc
2155 pMV261::nudCRv mc
2155 transformed with pMV261-NudCRv 5 10 0.5 10
mc
2155 pMV261::nudCBCG mc
2155 transformed with pMV261-NudCBCG > 200 200 0.5 10
mc
2155 DnudC mc
2155 knockout nudC 1 0.5 0.5 10
mc
2155 pMV261::nudCSm mc
2155 transformed with pMV261-NudCSm 200 50 0.5 10
BCG M. bovis BCG Pasteur1173P2 0.1 5 2.5 0.1
BCG pMV261 BCG transformed with pMV261 0.1 5 2.5 0.1
BCG pMV261::nudCRv BCG transformed with pMV261-NudCRv 0.1 5 2.5 0.1
BCG pMV261::nudCBCG BCG transformed with pMV261-NudCBCG > 2 > 50 2.5 0.1
BCG DnudC BCG knockout nudC 0.05 1 2.5 0.1
H37Ra M. tuberculosis H37Ra 0.1 1 2.5 0.01
H37Ra DnudC H37Ra knockout nudC 0.1 1 2.5 0.01
mc
2155 DnudC pMV261::nudCSm mc
2155 DnudC transformed with pMV261-NudCSm > 200 200 0.5 10
BCG DnudC pMV261::nudCBCG BCG DnudC transformed with pMV261-NudCBCG > 2 > 50 2.5 0.1
1382 X.-D. Wang etal. 
© 2011 Blackwell Publishing Ltd, Molecular Microbiology, 82, 1375–1391gene in M. smegmatis mc2155 and M. bovis BCG caused
increased susceptibility to both drugs. Since treatment
with INH or ETH leads to inhibition of mycobacterial
mycolic acid biosynthesis, we expect that changes in sus-
ceptibility to these drugs resulting from overexpression of
NudC or deletion of the nudC gene may alter their effect
on mycobacterial mycolic acid biosynthesis. Mycobacte-
rial strains (M. smegmatis mc2155, mc2155 DnudC,
mc2155 pMV261::nudCBCG, M. bovis BCG, BCG DnudC
and BCG pMV261::nudCBCG) were grown in the presence
INH and ETH at various concentrations, after which cul-
tures were labelled with 1, 2-[14C] acetate. Combined fatty
acid methyl esters (FAMEs) and mycolic acid methyl
esters (MAMEs) were extracted, resolved and fraction-
ated on TLC plates. Treatment of mc2155 DnudC with
INH (from 0 to 10 mgm l -1) (Fig. 5A) or ETH (from 0 to
500 mgm l -1) (Fig. 5B) resulted in very strong inhibition of
mycolic acid biosynthesis as shown by the absences of
MAMEs at a relatively low concentration of each drug
(1 mgm l -1 INH, 25 mgm l -1 ETH) compared with the wild-
type strain. On the contrary, INH (from 0 to 250 mgm l -1)
and ETH (from 0 to 500 mgm l -1) showed very weak
or nearly no inhibition of mycolic acid biosynthesis in
NudCBCG overexpressed M. smegmatis mc2155 strain
(mc2155 pMV261::nudCBCG) (Fig. 5A and B). Similarly,
INH and ETH inhibition of mycolic acid biosynthesis in
Fig. 4. INH and ETH mycobacterial killing curves. Mycobacterial cells were grown to mid-log phase (OD600 of 0.5–1.0) and diluted to about
10
6–10
7 cfu ml
-1 in fresh medium. INH or ETH was then added and aliquots were removed at regular intervals. Serial dilutions were performed
before plating.
A. M. smegmatis mc
2155 () and mc
2155 DnudC () with no drug added; M. smegmatis mc
2155 () and mc
2155 DnudC ( ) with 50 mgm l
-1
INH added.
B. M. bovis BCG () and BCG DnudC () with no drug added; M. bovis BCG () and BCG DnudC (	) with 5 mgm l
-1 INH added.
C. M. bovis BCG (
) and BCG DnudC ( ) with no drug added; M. bovis BCG () and BCG DnudC () with 50 mgm l
-1 ETH added.
Experiments were performed in triplicate. Standard deviations are indicated by error bars.
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© 2011 Blackwell Publishing Ltd, Molecular Microbiology, 82, 1375–1391BCG DnudC was markedly stronger compared with that in
the wild-type strain, while it was drastically diminished
by overexpression of NudCBCG (Fig. 5C and D). INH and
ETH at relatively low concentrations (0.1 mgm l -1 INH,
10 mgm l -1 ETH) completely abolished MAMEs synthesis
in BCG DnudC, while higher concentrations of the drugs
(0.5 mgm l -1 INH, 50 mgm l -1 ETH) were required to
achieve the same effect in the wild-type strain. On the
other hand, treatment of the NudCBCG overexpressing
strain BCG pMV261::nudCBCG with INH (from 0 to
1 mgm l -1) or ETH (from 0 to 50 mgm l -1) had a rather weak
or nearly no effect on the synthesis of MAMEs and
FAMEs.
Discussion
In this study, we report a unique character of
M. tuberculosis NAD metabolism, and propose a novel
mechanism of INH and ETH inactivation in mycobacteria.
NudC, the NADH pyrophosphatase, is a component of
NAD salvage pathway in many bacteria species including
mycobacteria. Protein sequence alignment showed that
NudC from M. tuberculosis H37Rv harbours a polymor-
phism at residue 237 that is not present in other
mycobacteria. Although this residue is conserved among
NudC from different species and is also predicted to be
one of the active site of the enzyme, so far no experimen-
tal data have been presented for this speciﬁc residue. In
this study, through comparative biochemical analysis of
puriﬁed NudCBCG and NudCRv, we found that the mutation
at residue 237 results in disruption of protein dimer for-
mation, changes in metal ion binding and loss of enzy-
matic activity. In addition, sequence analysis of nudC
genes ampliﬁed from 137 M. tuberculosis clinical isolates
from China revealed that nudC from most isolates har-
boured another mutation (residue 239), and a few isolates
even had multiple mutations. The standard laboratory
strain M. tuberculosis H37Rv was isolated in the year
1905. Since it was not possible to analyse the sequence
of nudC from different clinical isolates at that time, it is
now unclear whether the additional mutations of nudC
identiﬁed in clinical isolates here were already present
then or whether they have been acquired subsequently.
Biochemical analysis of the puriﬁed double mutant
NudCQR showed that the mutations at residues 237 and
239 lead to complete loss of enzymatic activity. Alignment
of mycobacterial NudC and E. coli NudC revealed that
residues P237 and P239 are both located in a very con-
served region (SQPWPFPQS) predicted to confer pyri-
dine nucleotide speciﬁcity (Dunn et al., 1999) (Fig. 1B),
suggesting that the mutation of these two residues may
affect the binding of substrates.According to the results of
amino acid sequence alignment, residue 237 of NudCRv
corresponds to residue 193 of E. coli NudC. The crystal
structure of E. coli NudC (PDB code 1vk6 and PDB code
2gb5) has been resolved and it was found to be a dimeric
protein. Residue 193 of E. coli NudC is located on the
surface of the interface between subunits (Fig. S9A and
B). It may thus be the case that the mutation of residue
237 in NudCRv affects the interaction between subunits,
causing the failure in protein dimerization observed here.
In addition, residue 239 of NudCRv corresponds to residue
195 in E. coli NudC. Residue 195 is also known to be
close to the surface of the protein interface between sub-
units (Fig. S9A and B). Thus it is not surprising to ﬁnd that
double mutation of residues 237 and 239 in NudCQR also
affect protein dimer formation. However, it is still remains
unclear whether protein dimerization is necessary for the
enzymatic activity of NudC.
From the above data, it is very clear that, in contrast to
M. bovis BCG and other mycobacteria, M. tuberculosis
H37Rv and most M. tuberculosis clinical isolates have
acquired mutations in the nudC gene, leading to the loss
of NADH pyrophosphatase activity. As mentioned above,
both residues 237 and 239 are located in a conserved
region (SQPWPFPQS) of NudC that is predicted to confer
pyridine nucleotide speciﬁcity. It is possible that NudCRv
may have gained additional as yet unknown functions,
which remain to be identiﬁed in further studies.
One unique property of M. tuberculosis NAD metabo-
lism is that it secretes niacin into the growth medium
under in vitro growth conditions, and previous research
revealed that, niacin secretion of M. tuberculosis was
mainly due to its high NAD glycohydrolase activity
(Kasa ˘rov and Moat, 1972). Here we report another unique
property of M. tuberculosis NAD metabolism. Most
M. tuberculosis clinical isolates have an inactive NADH
pyrophosphatase, although the reason remains unknown.
Previous studies have shown that NudC has a rather
broad range of substrates, including NADH/NAD+ and
nucleoside diphosphate derivatives (Frick and Bessman,
1995). This raises the possibility that, as homologues of
NAD, INH-NAD and ETH-NAD adducts could also be
substrates of NudC. We validated this hypothesis here by
biochemical assays including HPLC-MS. As expected,
NudCBCG was able to hydrolyse both adducts whereas
NudCRv was not. Since NudCBCG was capable of hydrol-
ysing INH-NAD and ETH-NAD, we reasoned that its over-
expression should lead to co-resistance to both drugs,
and that deletion of the nudC gene should result in
increased sensitivity to both drugs. This speculation
was veriﬁed by in vivo experiments. Overexpression of
NudCBCG in M. smegmatis mc2155 and M. bovis BCG
resulted in co-resistance to INH and ETH, but overexpres-
sion of NudCRv had no effect on susceptibility to
both drugs. Meanwhile, overexpression of NudCSm in
M. smegmatis mc2155 also resulted in co-resistance to
INH and ETH, suggesting that NudCSm is also functional
Mycobacterial NADH pyrophosphatase is a novel participant in isoniazid and ethionamide metabolism 1385
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On the other hand, deletion of the nudC gene in
M. smegmatis mc2155 and M. bovis BCG resulted in
increased susceptibility to INH and ETH in MIC tests.
More interestingly, inactivation of the nudC gene also
caused a defect in the INH or ETH tolerance phenotype
(Fig. 4). Furthermore, data from the analysis of mycolic
acids showed that overexpression of a functional NudC
effectively alleviated the inhibition of mycolic acid biosyn-
thesis caused by INH and ETH, and deletion of nudC
elevated the effects of both drugs on mycolic acid biosyn-
thesis (Fig. 5).
Based on the above results, we propose a novel
mechanism of INH and ETH inactivation in mycobacteria,
as shown in Fig. 6: INH and ETH are activated by KatG or
EthA, then form INH-NAD and ETH-NAD adducts with
NAD which inhibit the activity of InhA and result in inhibi-
tion of mycolic acid biosynthesis. Functional mycobacte-
rial NudC, however, can hydrolyse INH-NAD and ETH-
NAD adducts, blocking the effects of these drugs.
Inactivation of ETH and INH by mycobacterial NudC
was ﬁrst discovered in this manuscript; however, inactiva-
tion of INH by another mycobacterial enzyme Arylamine
N-acetyltransferase (NAT) was observed by other
researchers previously (Upton et al., 2001). The new
ﬁnding that mycobacterial NudC can also inactivate INH
adds to the complexity of metabolism of this drug in
mycobacteria.
ExceptforM. bovisBCG,whichwasveriﬁedtobeableto
inactivate INH and ETH through the new mechanism,
M. smegmatis mc2155 may also be able to inactivate both
drugs by the same mechanism according to our results.
Therefore it is important to investigate whether this new
mechanism exists in other mycobacteria, especially other
members of the M. tuberculosis complex. When compar-
ing the NudC sequence of M. bovis BCG with those from
clinical isolates of M. tuberculosis with known genome
sequences (http://www.broadinstitute.org/annotation/
genome/mycobacterium_tuberculosis_diversity/Genomes
Index.html), identical NudC sequences were found in the
three M. tuberculosis clinical isolates T46, CPHL_A and
EAS054 (Hirsh et al., 2004; Mostowy et al., 2004). This
indicates that, although the NudC from M. tuberculosis
H37Rv and most M. tuberculosis clinical isolates is inac-
tive, intact and functional NudC exists in a small portion of
M. tuberculosis clinical isolates, implying the new mecha-
nism of INH and ETH inactivation may also exist in these
isolates. This needs to be veriﬁed by further studies.
Experimental procedures
Bacterial strains, plasmids and media
Strains used are listed in Table S3. E. coli HB101 and E. coli
TOP10 were used for constructing mycobacterial mutant
strains. E. coli BL21 (DE3) was used as a host strain for
recombinant protein expression. M. smegmatis mc
2155,
M. bovis BCG and M. tuberculosis H37Ra were kindly pro-
vided by Dr William R. Jacobs Jr (Howard Hughes Medical
Institute, Albert Einstein College of Medicine). Plasmids
pET32a, pET28a (Novagen) and pMV261 (kindly provided by
Dr Guofeng Zhu) were used for construction of expression
plasmids. M. smegmatis mc
2155 was grown in Middlebrook
7H9 Broth or 7H10 agar medium (Difco) supplemented with
0.5% (v/v) glycerol and 0.05% (v/v) Tween-80. M. bovis BCG
and M. tuberculosis H37Ra were grown in Middlebrook 7H9
Broth or 7H10 agar medium (Difco) supplemented with 10%
(v/v) OADC (Difco), 0.5% (v/v) glycerol and 0.05% (v/v)
Tween-80. Antibiotics (Sigma) were added at the following
concentrations: kanamycin, 25 mgm l
-1 for mycobacteria and
50 mgm l
-1forE. coli;hygromycin,75 mgm l
-1formycobacteria
and 150 mgm l
-1 for E. coli, and ampicillin, 100 mgm l
-1 for
E. coli.
Molecular cloning
To generate expression constructs for puriﬁcation of NudC,
the nudC gene was ampliﬁed from M. bovis BCG and
M. tuberculosis H37Rv genomic DNA using primers NudCN-
coIFP and NudCXhoIRP (Table S3), digested with NcoI and
XhoI, and then ligated to the expression vector pET32a,
yielding pET32a-NudCBCG and pET32a-NudCRv. To generate
in vivo overexpression constructs, nudC from M. tuberculosis
H37Rv and M. bovis BCG were ampliﬁed using primers
261NudCBamHIFP and 261NudCHindIIIRP (Table S3),
digested with BamHI and HindIII, and then cloned into
pMV261, yielding pMV261-NudCBCG and pMV261-NudCRv.
nudC from M. smegmatis mc
2155 was ampliﬁed using
primers 261NudCBamHIFPSm and 261NudCHindIIIRPSm
(Table S3), digested with BamHI and HindIII, and then cloned
into pMV261, yielding pMV261-NudCSm. The inhA and
EthA genes of M. tuberculosis H37Rv were ampliﬁed using
primers InhANcoIFP/InhAHindIIIRP and EthABamHIFP/
EthAHindIIIRP (Table S3), inserted into the NcoI/HindIII sites
of pET28a and BamHI/HindIII sites of pET32a, creating
pET28a-InhA and pET32a-EthA respectively.
Protein expression and puriﬁcation
Recombinant strains E. coli BL21 (DE3)/pET32a-NudCBCG,
E. coli BL21 (DE3)/pET32a-NudCRv and E. coli BL21 (DE3)/
pET28a-InhA were all induced with 0.5 mM isopropyl b-D-
thiogalactopyranoside (IPTG) at 25°C for 10 h. Bacterial cells
wereharvested,suspendedinbindingbuffer(50 mMTris·HCl,
0.5 M NaCl, 25 mM imidazole, pH 8.0) and disrupted by
sonication.All proteins were puriﬁed by nickel affinity chroma-
tography. NudC protein used for analytical ultracentrifugation
was then puriﬁed by gel ﬁltration with a Superdex 200
10/300GL column (Pharmacia BioTech) which had previously
been equilibrated with 50 mM Tris-HCl buffer (pH 8.0). The
enzyme was eluted with 50 mM Tris-HCl buffer (pH 8.0), and
peak fractions containing the enzyme were pooled.
Analytical ultracentrifugation
The molecular weight of recombinant NudC was analysed
using an XL-I analytical ultracentrifuge (Beckman Coulter,
1386 X.-D. Wang etal. 
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Puriﬁed NudC (0.8 mg ml
-1 in 50 mM Tris·HCl, pH 8.0) was
centrifuged at 4°C under 40000 rpm for 4 h, using 50 mM
Tris-HCl buffer (pH 8.0) as a control. After ultracentrifugation,
data were analysed using SEDFIT (Schuck, 2000; http://
www.analyticalultracentrifugation.com/download.htm).
NudC activity assays
NudC activity was quantiﬁed by measuring the conver-
sion of the phosphatase-insensitive substrate NADH to
phosphatase-sensitive products AMP and NMNH (Xu et al.,
2000). The standard reaction mixture (50 ml) contained:
50 mM Tris-HCl, pH 8.0; 5 mM MgCl2; 2.5 mM NADH; 4 units
of calf intestine alkaline phosphatase (EC 3.1.3.1) and 0.2–2
milliunits of enzyme. After incubation at 37°C for 15 min, the
reaction was terminated by addition of 250 ml of 4 mM EDTA.
Inorganic orthophosphate was measured as previously
reported (Ames and Dubin, 1960).Aunit of enzyme catalysed
the hydrolysis of 1 mmol of NADH per min under these
conditions.
Synthesis and isolation of INH-NAD and
ETH-NAD adducts
First, the [Mn
III(H2P2O7)3]Na3 complex which is necessary
for synthesis of the INH-NAD adduct was synthesized as
previously described (Nguyen et al., 2001). In brief, an
aqueous solution of sodium pyrophosphate (200 mM) con-
taining Mn
III(OAc)3 (5.5 mM) was acidiﬁed to pH 4.5 (or pH
6.5) with pyrophosphoric acid, then stirred at RT for 24 h.
The INH-NAD adduct was then synthesized as reported
(Nguyen et al., 2002). The reaction mixture containing
100 mM phosphate buffer (pH 7.5), 2 mM INH, 2 mM NAD
and 4 mM Mn(III) pyrophosphate (introduced in 10 consecu-
tive additions of 400 mM each, every 2 min) was stirred at
RT for 20 min after addition of the last ingredient. To isolate
the INH-NAD adduct, puriﬁed InhA (400 mM) was added
into the above reaction mixture and stirred at RT for 2 h.
The sample was then concentrated and the buffer was
exchanged with 50 mM Tris-HCl by using a Millipore Amicon
Ultra 10 K centrifugal device. The InhA-adduct complex was
denatured by boiling for 40 s and immediately cooling on ice
and then transferred into a Microcon 3 centricon ﬁlter unit
and spun to recover the released adduct in the ﬁltrate (Lei
et al., 2000). The ETH-NAD adduct was synthesized as pre-
viously described (Wang et al., 2007). Brieﬂy, the plasmids
pET28a-InhA and pET32a-EthA were co-transformed into
E. coli BL21 (DE3). The strain containing these two plas-
mids was cultured in LB media containing 50 mgm l
-1 kana-
mycin and 100 mgm l
-1 ampicillin at 37°C until OD600
reached 0.8, then induced at 16°C for 20 h by addition of
0.5 mM IPTG. ETH of 100 mgm l
-1 was also added to the
culture during induction. Recombinant InhA was puriﬁed
according to the above method. The InhA puriﬁed from the
strains containing both pET28a-InhA and pET32a-EthA
plasmids was concentrated and heated for 40 s at 100°C.
After heat treatment, ETH-NAD was separated from the
denatured InhA by ﬁltration using a Microcon 3 centricon
ﬁlter unit.
HPLC-MS analysis of INH-NAD and ETH-NAD adducts
and their NudC hydrolysis products
The INH-NAD adduct and its NudC hydrolysis products
were analysed by HPLC-ESI/MS (Shimadzu LCMS-2010EV,
Tokyo, Japan). HPLC separations were performed according
to Rawat (Rawat et al., 2003). A Shim-pack VP-ODS column
(Shimadzu, 250 ¥ 2.0 mm i.d., 5 mm) ﬁtted with a C18 guard
column (Shimadzu) was used. ESI/MS working parameters
were as follows: capillary voltage was 4.5 kV, curved desol-
vation line (CDL) was 250, and heat block temperatures for
the analysis was set at 200°C. Nitrogen drying and nebulizer
gases were set at 1.5 l min
-1 with a pressure of 0.02 MPa.
The detector voltage was set at 1.4 eV. The ETH-NAD adduct
and its NudC hydrolysis products were analysed on a HPLC-
MicrOTOF_Q mass spectrometer (Agilent 1200 HPLC and
Bruker Daltonic MicrOTOF_Q mass spectrometer). HPLC
separations were carried out under the same conditions as
those for INH-NAD. The ESI/MS working parameters were as
follows: the ESI source was operated with a nebulizer pres-
sure of 0.8 bar while the drying gas was delivered at a ﬂow
rate of 8 l min
-1 and the capillary voltage was 4000 V. All MS
data were acquired in a scan range between 200 and
1000 m/z under the negative ionization mode.
Construction of mycobacterial mutant strains
Temperature-sensitive specialized transducing phasmids
(Bardarov et al., 2002) were constructed and used for allelic
exchange-mediated deletion of the nudC gene in different
mycobacteria (MSMEG_1946, Rv3199c/MRA_3236 and
BCG_3224c). DNA segments of approximately 1 kb ﬂanking
the gene of interest were ampliﬁed by PCR, digested with
Van91I and ligated to compatible fragments of the counter-
selectable vector p0004S (a kind gift from Dr William R.
Jacobs Jr). Allelic exchange plasmids were selected and
propagated following transformation of E. coli TOP10 to
hygromycin resistance. Sequences of inserted DNA frag-
ments were veriﬁed.Allelic exchange plasmids were digested
with PacI and ligated to PacI-digested phAE159 (Lee et al.,
2004). Ligation products were packaged using MaxPlax™
Lambda Packaging Extracts (EPICENTRE Biotechnologies,
USA) and transduced into E. coli HB101 for propagation as
cosmids. Cosmid DNA was puriﬁed and electroporated
into M. smegmatis mc
2155 for phage propagation at the per-
missive temperature (30°C). Subsequently, M. smegmatis
mc
2155 strains were transduced at the non-permissive tem-
perature (37°C) and recombinant strains with integration of
the allelic exchange marker were selected on LB agar plates
containing hygromycin. Integration of the allelic exchange
marker at the locus of interest was veriﬁed by PCR using one
primer that anneals within the exchange marker and one
primer that anneals distal to the genomic region that was
involved in allelic exchange.
Drug susceptibility tests
Mycobacterial cells were grown to mid-log phase (OD600 of
0.5–1.0) and diluted to 10
6 cfu ml
-1 (cfu, colony-forming unit)
in fresh 7H9 medium. Then 10-fold serial dilutions were
1388 X.-D. Wang etal. 
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centrations of different drugs: for M. smegmatis mc
2155
strains, INH (0, 0.1, 0.25, 0.5, 1.25, 2.5, 5, 10, 25, 50, 100,
150, 200 mgm l
-1), ETH (0, 0.1, 0.25, 0.5, 1.25, 2.5, 5, 10, 25,
50, 100, 150, 200 mgm l
-1), EMB (0, 0.1, 0.25, 0.5, 1, 2.5,
5 mgm l
-1) and RIF (0, 5, 10, 25, 50, 75, 100 mgm l
-1); for
M. bovis BCG and M. tuberculosis H37Ra strains, INH (0,
0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8, 1, 2 mgm l
-1), ETH (0, 2.5, 5,
10, 15, 20, 50 mgm l
-1), EMB (0, 0.1, 0.25, 0.5, 1, 2.5, 5,
10 mgm l
-1) and RIF (0, 0.005, 0.01, 0.05, 0.1, 0.25,
0.5 mgm l
-1). Cultures were incubated for 3 days (for
M. smegmatis mc
2155) or 21 days (for M. bovis BCG and
M. tuberculosis H37Ra) at 37°C. MIC was deﬁned as the
lowest concentration of compound required to inhibit 99% of
bacterial cfu.
Drug exposure experiments
Mycobacterial cells were grown to mid-log phase (OD600 of
0.5–1.0) and diluted to about 10
6–10
7 cfu ml
-1 in fresh 7H9
medium with or without 10% OADC. For INH treatment of
M. smegmatis mc
2155, 50 mgm l
-1 INH were added to each
sample, for that of M. bovis BCG, 5 mgm l
-1 INH was added to
each sample. For ETH treatment of M. bovis BCG, 50 mgm l
-1
ETH was added to each sample. Aliquots of samples were
taken at regular intervals and serial dilutions were performed
before plating.
Analysis of mycobacterial mycolic acids following ETH
and INH treatment
Extraction of cell wall mycolic acids from mycobacterial cells
was carried out as previously described (Baulard et al.,
2000). M. smegmatis mc
2155 or M. bovis BCG cultures (5 ml)
were grown to mid-log phase (OD600 ª 0.3), then ETH or INH
was added at various concentrations followed by further incu-
bation for 4 h (for M. smegmatis mc
2155) or 24 h (for M. bovis
BCG). At this point, 1, 2-[
14C] acetate (1 mCi ml
-1) was added
and the cultures were further incubated with gentle agitation
at 37°C for 4 h (for M. smegmatis mc
2155) or 24 h (for
M. bovis BCG). After centrifugation, cell pellets were washed
once with distilled water and then resuspended in 3 ml of
15% tetrabutylammonium hydroxide (TBAH). The cell sus-
pension was heated at 100°C overnight. After cooling, water
(2 ml), dichloromethane (1 ml) and iodomethane (250 ml)
were added, and the entire reaction mixture was agitated for
30 min. After centrifugation, the upper aqueous phase was
discarded and the lower organic phase was washed twice
with water, dried in a sand bath, and the residue was resus-
pended in methylene chloride. The radiolabelled extracts
were separated by thin-layer chromatography (TLC) on a
silica gel 60 F254 plate and developed once in petroleum
ether: acetone (95:5, v/v). Subsequent autoradiography
revealed
14C-labelled FAMEs and MAMEs after overnight
exposure of the TLC plates to Kodak BioMax MR ﬁlm.
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